AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06557772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: SIGE
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT06557772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten-free product (GFP)
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT06557772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Gluten-free product (GFP)
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT06312137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: Sacituzumab tirumotecan to be administered as 4mg/kg IV infusion q2w for up to 40 weeks
Study NCT06312137 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
Study NCT06312137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab to be administered 400mg by IV infusion q6w for up to 42 weeks
Study NCT06312137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is administered as 75 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in neoadjuvant phase
Study NCT06312137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered in the neoadjuvant phase as 500 mg/m2 IV infusion q3w for up to 12 weeks as background treatment in participants with nonsquamous NSCLC.
Study NCT06312137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered in the neoadjuvant phase as 1000 mg/m2 or 1250 mg/m2 IV infusion on day 1 and day 8 q3w for up to 24 weeks as background treatment in participants with squamous NSCLC.
Study NCT06312137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered in the neoadjuvant phase as AUC 5 mg/mL/min or AUC 6 mg/mL/min IV infusion q3w for up to 12 weeks as background treatment.
Study NCT06208696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomando control de su salud (Spanish Chronic Disease Self-Management)
Description: Tomando control de su salud (Spanish Chronic Disease Self-Management) is a culturally appropriate program developed in Spanish to support Hispanics patients to build confidence in their ability to manage their health. This intervention was developed by Lorig et al. at Stanford University and has been widely used by the Puerto Rico Department of Health since it is recommended by the CDC as an evidenced-based intervention for chronic disease management.
Study NCT06312137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered in the neoadjuvant phase as 175 mg/m2 or 200 mg/m2 IV infusion q3w for up to 12 weeks as background treatment.
Study NCT06562595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Training will be provided to the participants, with the objective of determining the most accurate training method on HPV and cervical awareness.
Study NCT04971109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPOXX
Description: Study is based on Animal Regulatory Rule
Study NCT06654401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: Standard assessment of the parameters of the left atrium: size, volume, volume indices
Study NCT06654401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transthoracic echocardiography
Description: Standard assessment of the parameters of the left atrium: size, volume, volume indices
Study NCT06654401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24-hour ECG Monitor
Description: Assessment of cardiac arrhythmias according to 24-hour monitoring data
Study NCT06654401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 24-hour ECG Monitor
Description: Assessment of cardiac arrhythmias according to 24-hour monitoring data
Study NCT06654401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping
Description: Intraoperative assessment of low voltage areas (potential fibrosis zones)
Study NCT06654401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroanatomic mapping
Description: Intraoperative assessment of low voltage areas (potential fibrosis zones)
Study NCT04950582 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spectral characteristics assessment
Description: Urine sample analysis for evidence of urinary tract infection
Study NCT04230395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAP
Description: 4-session combination Motivational Enhancement Therapy and Cognitive Behavioral Therapy alcohol reduction intervention. The intervention will also include 3 booster sessions.
Study NCT04230395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Provider advice to reduce alcohol use per recommended standard of clinical care, and referral to treatment as indicated
Study NCT05021601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bi-atrial ablation
Description: This intervention includes mitral valve surgery concomitant with left atrial ablation and right atrial ablation.
Study NCT05021601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial ablation
Description: This intervention includes mitral valve surgery concomitant with left atrial ablation alone.
Study NCT05797675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prf + osseodensification
Description: prf+ osseodensification in close sinus lift
Study NCT05841134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Neoadjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, D1, Q3W, a total of 4 cycles; Oxaliplatin 130mg/m2, intravenous infusion, D1, Q3W, 4 cycles in total; Capecitabine 1000mg/m2, orally twice in the morning and evening, D1-14, Q3W, 4 cycles in total;~Adjuvant treatment options:~Tislelizumab 200mg, intravenous infusion, Q3W;~± Chemotherapy method (researcher judges whether to add chemotherapy according to the comprehensive condition of the patient); Until disease progression or unacceptable toxicity, the maximum treatment time is 12 months.
Study NCT05466838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PERT at discharge
Description: Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day. Dose escalation 100,000 units lipase with meals and 50,000 units with snacks.
Study NCT04971109 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TPOXX Placebo
Description: Does not apply
Study NCT05871970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TARA-002
Description: All participants will receive up to 4 intracystic injections spaced approximately 6 weeks apart.
Study NCT05466838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Initiation of PERT if clinical symptoms of PEI develop or worsen. Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day.
Study NCT05466838 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Initiation of PERT if clinical symptoms of PEI develop or worsen. Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day.
Study NCT06683209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Schocket scleral depressor
Description: Use of this instrument to examine one eye
Study NCT05196776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable, handheld point-of-care ultrasound device
Description: The patient will have an ultrasound performed using a handheld, portable device.
Study NCT05196776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cart-based point-of-care ultrasound device
Description: The patient will have an ultrasound performed using a traditional cart-based model.
Study NCT06565793 — intervention group
Intervention type: DEVICE
Intervention: Non Complex PCI
Description: The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).
Study NCT06565793 — intervention group
Intervention type: DEVICE
Intervention: Complex PCI
Description: The patient cohort included individuals who had been hospitalized with a diagnosis of either STEMI or non-STEMI. The procedure involved complex percutaneous coronary intervention (PCI) with the use of drug-eluting stents (DES).This designation is applied to angioplasty procedures that meet at least one criterion for complexity. The complex angioplasty involved patients with unprotected left coronary common trunk (UT-PCI), the use of rotablator rotary atherectomy (ARota-PCI), the angioplasty of chronic coronary occlusion (CCO-PCI), or the angioplasty of a bifurcation lesion (CBL-PCI).The highly intricate angioplasty procedure was conducted on patients who met at least two criteria indicative of complexity.
Study NCT06503185 — intervention group
Intervention type: BEHAVIORAL
Intervention: Prehabilitation
Description: The intervention is a home-based, multimodal exercise prehabilitation program. Exercise is prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
Study NCT06250608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse oximeter, NIRSITX
Description: It is a device that non-invasively continuously monitors blood oxygen saturation (rSO2) in localized areas of the brain. This device is attached to patients with symptoms suspected of stroke or diagnosed with stroke to continuously monitor the level of oxygen supply to the brain.
Study NCT05693948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other: Serum X
Description: Serum X contain arbutin and glutathione
Study NCT04843020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION 682884
Description: Subcutaneous injection every month
Study NCT06040931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopy and broncho-alveolar lavage (BAL) to assess neutrophilic count in BAL as a measurement of airway inflammation
Study NCT06683209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Josephberg-Besser
Description: Use of this instrument to examine one eye
Study NCT06683209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cotton tip applicator
Description: Use of this instrument to examine one eye
Study NCT06281457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulus properties: task-defining feature
Description: The feature used to determine which stimulus feature to attend to will be varied across trials using a letter cue (M = motion-attend, C = color-attend, F = fixation-attend)
Study NCT06532188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypno-ear-acupuncture
Description: 5 acupuncture permanent needles on ear acupuncture points according to the National Acupuncture Detoxification Association (NADA) protocol, needle retention after 7 days standardized medical hypnosis:~* Induction of a trance~* suggestions for calm and good sleep
Study NCT06532188 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Hypno-ear-acupuncture
Description: 5 acupuncture permanent needles on ear acupuncture points inserted at non-specific points on the backside of the outer ear, needle retention after 7 days standardized sham hypnosis~- story without trance induction and suggestions
Study NCT04660539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: satralizumab
Description: Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years
Study NCT04660539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine (AZA)
Description: Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
Study NCT04660539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (MMF)
Description: Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day
Study NCT04660539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral corticosteroids
Description: Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
Study NCT06747702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury prevention workout
Description: The injury prevention workout consisted on engaging on a prevention program from 1 day to 8 weeks where the participants will develop functional sport exercises to prevent shoulder injuries or pain in overhead sports.
Study NCT06747676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active: High-Definition transcranial Direct Current Stimulation (HD-tDCS)
Description: Active high-definition transcranial direct current stimulation (HD-tDCS) will be delivered by a low-intensity direct current stimulator (Soterix Medical) using a 3x1 ring configuration with a central cathode over the contralesional temporo-parietal junction. During the stimulation, participants will perform tasks to stimulate correct visual verticality perception. Six active HD-tDCS sessions of 2mA for 20 minutes HD-tDCS, 3 times daily for 2 days with session intervals greater than 3 hours.
Study NCT06747676 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham: High-Definition transcranial Direct Current Stimulation (HD-tDCS)
Description: Six sessions (3 times daily for 2 days) of 2mA sham HD-tDCS cathode center over the contralesional TPJ for 20min. Direct current (DC) will be generated by a low-intensity direct current stimulator (Soterix Medical) and then split into the 3 high-density Ag/AgCl sintered ring electrodes. The sham stimulation condition will consist of the same positioning of the electrodes as the active condition, with a ramp-up to 2mA over 30 seconds and a subsequent ramp-down of 30 seconds.
Study NCT04747457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Research FibroScan
Description: After having obtained the patient's Informed Consent Form signature, the following 3 examinations will be done:~1. Standard examination \[Reference CE-marked FibroScan\]: the operator will need to find an optimal measurement area, and perform 10 valid measurements.~2. Standard examination \[Research FibroScan\]: the operator must take 15 valid measurements at the same measurement point as the one used for the examination with the Reference FibroScan.~3. Exploratory examination \[Research FibroScan\]: the operator needs to perform15 invalid measurements to acquire data in non-optimal regions of measurement (lungs, vessels, intestines, ribs, edges of the liver).
Study NCT05193630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milnutri Sure™
Description: Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water.
Study NCT05193630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milnutri Sure™
Description: Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml).~For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water.
Study NCT06747663 — intervention group
Intervention type: PROCEDURE
Intervention: Needle Depth Measurement Using MRI, Ultrasound, and Fluoroscopy
Description: This intervention involves cervical epidural steroid injection (CESI) for patients with chronic neck and radicular pain. Needle depth is measured pre-procedurally using MRI and ultrasound to predict the ideal needle placement. Fluoroscopy is used during the procedure to confirm and compare these measurements, aiming to evaluate the accuracy of imaging techniques and minimize radiation exposure.
Study NCT06218914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NT-112: Autologous, engineered T Cells targeting KRAS G12D
Description: * Pre-conditioning by non-myeloablative chemotherapy with fludarabine and cyclophosphamide~* Single infusion of T cell receptor (TCR) T cells~* Post-infusion recombinant interleukin-2 (rIL-2)
Study NCT05647811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.
Study NCT05130333 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05678465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-fixation of the mesh
Description: 3D-shaped, anatomical, standard, polypropylene mesh without fixation.
Study NCT05678465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixation of the mesh
Description: Glue fixation of lightweight, macroporous, polypropylene mesh.
Study NCT06572293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention
Description: Nurse-led intervention involves patient education, collecting Patient Reported Outcomes (PRO) and evaluating them by specialists nurses, as well as navigating patients to services that can assist with their symptoms. During three-five planned appointments, the nurse will talk with you about adjusting to life after complete the radiotherapy of nasopharyngeal carcinoma, including symptoms of relapse and how to deal with them.In the first year, PROs will be collected every six months on recurrences and late effects, and thereafter every 12 months. PRO will be administered to patients for three years after the nurse appointments are finalized.
Study NCT06645184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral nutritional supplement
Description: During 4 test days, 1 bottle (125ML) of High protein ONS with or without fibre and with or without the added nutrients will be consumed by the subjects. During each test day, the subjects will complete questionnaires related to appetite and liking of the product from baseline (-5 minutes of start consumption of study product) until 120 minutes after start consumption of study product.
Study NCT05154734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
Study NCT06407297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: Peripheral intravenous infusion of umbilical cord mesenchymal stem cells
Study NCT06407297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Peripheral intravenous infusion of Placebo
Study NCT05039281 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT04795960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low serine diet
Description: Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
Study NCT04795960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High serine diet
Description: Participants will be on this diet 1 week prior to initiation and 1 week after initiation of Ustekinumab (standard of care medication). The meals will be prepared in the Michigan Clinical Research Unit (MCRU) at the University of Michigan Health System and given to the participants.
Study NCT05039281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT05913674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified early post-operative intraperitoneal chemotherapy (mEPIC)
Description: On post-operative days 1 and 2, an abdominal reservoir is obtained by administering 1000 mL of plasmalyte with 50 mEq NaHCO3 via a Tenckhoff catheter. Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil infusion of 1200 mg/m2 over the next 24 hours. During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.~After completion of mEPIC day 1, the perfusate is drained out before starting mEPIC day 2.
Study NCT06563765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAP-targeting PET/CT imaging will be performed on the enrolled patients.
Description: FAP-targeting PET/CT imaging will be performed on the enrolled patients.